Journal of Cardiovascular Pharmacology最新文献_第3页

Sodium Glucose Cotransporter 2 Inhibitors Improve Long-term Atrial Fibrillation-free Survival After Catheter Ablation. 钠葡萄糖共转运蛋白2抑制剂改善导管消融后长期无房颤生存。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001656

Aykun Hakgor, Fatih Erkam Olgun, Atakan Dursun, Basak Catalbas Kahraman, Aysel Akhundova, Umeyir Savur, Mehmet Besiroglu, Melike Zeynep Kenger, Emir Dervis, Busra Guvendi Sengor, Fethi Kilicaslan

{"title":"Sodium Glucose Cotransporter 2 Inhibitors Improve Long-term Atrial Fibrillation-free Survival After Catheter Ablation.","authors":"Aykun Hakgor, Fatih Erkam Olgun, Atakan Dursun, Basak Catalbas Kahraman, Aysel Akhundova, Umeyir Savur, Mehmet Besiroglu, Melike Zeynep Kenger, Emir Dervis, Busra Guvendi Sengor, Fethi Kilicaslan","doi":"10.1097/FJC.0000000000001656","DOIUrl":"10.1097/FJC.0000000000001656","url":null,"abstract":"Abstract: Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) are known to reduce the incidence of atrial fibrillation (AF) and AF-related adverse events, evidence on their prognostic effect in patients undergoing catheter ablation (CA) for AF is limited. In a single center, 614 patients (mean age 58.1 ± 9.9 years, 42.2% female) who underwent CA for AF were retrospectively divided into 2 groups according to SGLT2i treatment after the index procedure and followed up for 24 months. The primary outcome of the study was AF recurrence after the first 90-day blanking period after CA. Two separate Cox regression models were constructed to determine the predictors of AF recurrence. Rates of the primary outcome were 19.4% and 35.7% in the SGLT2i and non-SGLT2i groups, respectively. According to the multivariable model 1, which was established among the clinically relevant variables that were found to be statistically significant in univariable analysis, left atrial diameter (adjusted HR: 1.087, 95% CI, 1.054-1.122, P < 0.001), SGLT2i therapy (adjusted HR: 0.436, 95% CI, 0.286-0.665, P < 0.001), and nonparoxysmal AF (adjusted HR: 1.549, 95% CI, 1.039-2.309, P = 0.032) were independent predictors of recurrence after ablation. In model 2, SGLT2i treatment remained an independent predictor of AF recurrence along with significant variables such as age, heart failure with reduced ejection fraction, and previous stroke (adjusted HR: 0.315, 95% CI, 0.214-0.461, P < 0.001). The favorable efficacy of SGLT2i on the primary outcome was maintained in subgroup analyses. SGLT2i treatment is associated with lower recurrence after CA for AF in subgroups with and without diabetes or heart failure with reduced ejection fraction and in the overall patient population, independent of AF phenotype.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"225-232"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digoxin Loading Doses and Serum Digoxin Concentrations for Rate Control of Atrial Arrhythmias in Critically Ill Patients. 用于控制重症患者房性心律失常的地高辛负荷剂量和血清地高辛浓度。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001648

Tania Ahuja, Raghad Saadi, John Papadopoulos, Samuel Bernard, Raymond Pashun, James Horowitz, Eugene Yuriditsky, Cristian Merchan

{"title":"Digoxin Loading Doses and Serum Digoxin Concentrations for Rate Control of Atrial Arrhythmias in Critically Ill Patients.","authors":"Tania Ahuja, Raghad Saadi, John Papadopoulos, Samuel Bernard, Raymond Pashun, James Horowitz, Eugene Yuriditsky, Cristian Merchan","doi":"10.1097/FJC.0000000000001648","DOIUrl":"10.1097/FJC.0000000000001648","url":null,"abstract":"Abstract: Intravenous (IV) digoxin loading dose (LD) recommendations for rate control of atrial arrhythmias in critically ill patients are not well studied. When using digoxin in the setting of atrial fibrillation/atrial flutter (AF/AFL), a LD in either a fixed-dose regimen, weight-based dose, or pharmacokinetic-based calculation to target a serum digoxin concentration (SDC) of 0.8-1.5 ng/mL is recommended. The objective of this study was to assess the safety and effectiveness of digoxin LD used in critically ill patients for rate control of AF/AFL and to assess the SDC achieved. This single-center retrospective cohort study included patients, who received IV digoxin and had a SDC drawn. The primary endpoint was the median SDC achieved after a digoxin LD. Secondary outcomes included the frequency of SDCs ≥1.5 ng/mL and heart rate control. A total of 92 patients were included. The median total LD of digoxin for the entire cohort was 11 μg/kg (750 μg). For 61% of the cohort, the LD was distributed over 6-hour intervals. The median SDC after completion of the IV digoxin LD was 1.3 ng/mL (0.9-1.7). The incidence of supratherapeutic SDC was 36% for the total cohort. A target heart rate <110 beats per minute within 24 hours from digoxin LD was achieved in 60% of the cohort. In conclusion, a median total digoxin LD of 750 μg in critically ill patients with AF/AFL, targeting a SDC <1.5 ng/mL, may be considered for acute rate control, taking into account drug-drug interactions in the cardiac intensive care unit. Future studies are necessary to confirm our findings.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"211-216"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting Vulnerability Status of Carotid Plaques Using CTA-Based Quantitative Analysis. 基于cta的定量分析预测颈动脉斑块易损状态。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001664

Qun Lao, Rongzhen Zhou, Yitian Wu, ChangFeng Feng, Jianxin Pang, Ling Ma, Yunjun Yang, Wenbin Ji

{"title":"Predicting Vulnerability Status of Carotid Plaques Using CTA-Based Quantitative Analysis.","authors":"Qun Lao, Rongzhen Zhou, Yitian Wu, ChangFeng Feng, Jianxin Pang, Ling Ma, Yunjun Yang, Wenbin Ji","doi":"10.1097/FJC.0000000000001664","DOIUrl":"10.1097/FJC.0000000000001664","url":null,"abstract":"Abstract: The study aimed to develop a radiomics model to assess carotid artery plaque vulnerability using computed tomography angiography images. It retrospectively included 107 patients with carotid artery stenosis who underwent carotid artery stenting from 2017 to 2022. Patients were categorized into stable and vulnerable plaque groups based on pathology. A training group and a testing group were formed in a 7:3 ratio. Clinical data, including demographics and lipid profiles, were collected alongside pretreatment computed tomography angiography images. Radiomics features were extracted and reduced using the LASSO method to minimize redundancy. A radiomics model was then constructed, using 13 features with a minimum penalty coefficient logλ = 0.047. Significant differences were found between stable and vulnerable plaques in terms of stenosis degree. The radiomics model showed high accuracy (area under the curve of 0.959 in training and 0.942 in testing) for identifying vulnerable plaques. When combined with clinical parameters stenosis degree, the model's diagnostic efficacy improved further, with area under the curve values of 0.985 and 0.961 in the training and testing groups, respectively. Decision curve analysis indicated that the combined model offered superior clinical benefits for the clinical model and radiomics model alone. The study concludes that the combined radiomics model, incorporating stenosis degree, presents a promising tool for differentiating vulnerable from stable plaques.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"217-224"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing Digoxin Use for Rate Control in Critically Ill Patients With Atrial Arrhythmias: Lessons From a Retrospective Study. 优化地高辛用于控制危重心房心律失常患者的心率：来自回顾性研究的经验教训。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001668

Marco Giuseppe Del Buono, Simone Filomia, Tommaso Sanna

引用次数: 0

Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction, Erratum. 非奈酮对保留射血分数的心力衰竭有益，勘误。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001676

Giuseppe Biondi-Zoccai, Mattia Galli, George W Booz

引用次数: 0

Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity. 白细胞介素-1阻断剂在ST段抬高型心肌梗死患者中的应用跨越了冠状动脉疾病复杂性的范围。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001652

Martin Denicolai, Matteo Morello, Michele Golino, Giuliana Corna, Marco G Del Buono, Carla R Agatiello, Benjamin W Van Tassell, Antonio Abbate

{"title":"Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity.","authors":"Martin Denicolai, Matteo Morello, Michele Golino, Giuliana Corna, Marco G Del Buono, Carla R Agatiello, Benjamin W Van Tassell, Antonio Abbate","doi":"10.1097/FJC.0000000000001652","DOIUrl":"10.1097/FJC.0000000000001652","url":null,"abstract":"Abstract: Patients with ST-segment elevation myocardial infarction (STEMI) and complex coronary artery disease (CAD) face a poor prognosis, including increased heart failure (HF) risk. Phase 2 clinical trials of anakinra have shown inhibition of the acute inflammatory response and prevention of HF after STEMI, but data on its effects based on CAD complexity are lacking. We performed a pooled secondary analysis of 139 patients with STEMI. The SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery), SYNTAX II, and Gensini scores were calculated, and patients were divided into 2 groups below and above the median. We evaluated the effect of anakinra on the area-under-the-curve of high-sensitivity C-reactive protein (hsCRP-AUC) at 14 days, and the composite endpoint of new-onset HF, HF hospitalization, or all-cause death at 1-year follow-up using Kaplan-Meier survival curves, Cox regression analysis for hazard ratios (HRs), and tested interactions between subgroups. All 3 CAD complexity scores (SYNTAX, SYNTAX II, and Gensini) were associated with an increased risk of adverse events (HR 1.02-1.06, all P-values ≤0.025). We found no statistically significant interactions between CAD extent, measured as single-vessel or multivessel CAD, SYNTAX score ≤9 or >9, SYNTAX II score ≤24 or >24, Gensini score ≤32 or >32, and treatment effect of anakinra on hsCRP-AUC or the composite clinical endpoint (all P - values for interaction >0.05). In conclusion, among patients with STEMI, IL-1 blockade with anakinra significantly attenuated the acute inflammatory response and reduced the risk of HF-related events regardless of the spectrum of CAD complexity.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"200-210"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Studying the Pathologic Mechanisms and Treatment Strategies of Transthyretin Amyloidosis. 转甲状腺素淀粉样变的病理机制及治疗策略研究进展。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001663

Hongyin Chen, Ruonan Liu, Siqi Luo, Jinzi Su

引用次数: 0

Interleukin-1 Blockade in Myocardial Infarction and Its Efficacy in Patients With Complex Coronary Artery Disease: Another Brick in the Wall. IL-1阻断在心肌梗死中的作用及其在复杂冠状动脉疾病患者中的疗效墙上又添了一块砖。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-03-01 DOI: 10.1097/FJC.0000000000001666

Matthew Sadler, Cristina Madaudo, Antonio Cannata, Daniel Bromage

引用次数: 0

Pantothenate Kinase 1 (PANK1) Identified as a Direct Target of SGLT2 Inhibitors in the Heart. 泛酸激酶1 （PANK1）被确定为心脏中SGLT2抑制剂的直接靶点。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-28 DOI: 10.1097/FJC.0000000000001689

Ghadir Amin, George W Booz, Fouad A Zouein

引用次数: 0

Coupling Interval Ratio to Predict the Beta Blocker Response against Premature Ventricular Complexes. 偶联间隔比预测β受体阻滞剂对早衰心室复合体的反应。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-02-28 DOI: 10.1097/FJC.0000000000001686

Hasan Atmaca, Ertan Yetkin

{"title":"Coupling Interval Ratio to Predict the Beta Blocker Response against Premature Ventricular Complexes.","authors":"Hasan Atmaca, Ertan Yetkin","doi":"10.1097/FJC.0000000000001686","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001686","url":null,"abstract":"Despite the wide-spread use of beta blockers, unpredictable response and overall low efficacy are the major pitfalls of beta blocker use for premature ventricular complexes (PVC). Accordingly, we aimed to reveal Holter-guided electrocardiographic criteria to predict the beta blocker responder ones of PVCs. A total of 89 patients who had pre- and post- treatment Holter ECG recordings and fulfilled the inclusion criteria were retrospectively included in the study. Holter recordings were screened for heart rate variability (HRV), numbers of PVC, heart rate, pre and post coupling intervals (CI) in three different time intervals (24:00 to 08:00am, 08:00 am to 16:00 pm and 16:00pm to 24:00) . Forty three patients were defined as beta blocker responder group in respect to 70% decrease in PVCs burden. HRV analysis revealed that there were not statistically significant differences between beta blocker responder and non-responder group. CI ratio ((post-PVC CI+ pre-PVC CI)/Pre-PVC CI) of responder and non-responder groups in 24.00 to 8.00 am time interval was statistically different (3.19 vs. 2.91, p=0.006 respectively). Logistic regression analysis revealed that CI ratios of the PVCs during the 24:00-08:00 am intervals have significantly associated with the beta blocker responsiveness for PVCs (Odds ratio: 9.54 95% CI: 1,89-48.7, P value: 0.006) Night-time increased CI ratio i.e shorter CI time has been found to be an independent predictor of beta blocker response against PVCs. Therefore, beta blockers may be preferably recommended for PVCs, especially in those with shorter CI or increased CI ratio.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0